EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment

医学 异环磷酰胺 依托泊苷 化疗 养生 中性粒细胞减少症 外科 骨肉瘤 化疗方案 内科学 病理
作者
Jeremy Whelan,Stefan Bielack,Neyssa Marina,Sigbjørn Smeland,Gordana Jovic,Jane Hook,Mark Krailo,Jakob Anninga,Trude Butterfaß‐Bahloul,Tom Böhling,Gabriele Calaminus,Michael Capra,Claudia Deffenbaugh,Catharina Dhooge,Mikael Eriksson,Adrienne M. Flanagan,Hans Gelderblom,Allen M. Goorin,Richard Görlick,Georg Gosheger
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:26 (2): 407-414 被引量:303
标识
DOI:10.1093/annonc/mdu526
摘要

Four international study groups undertook a large study in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based on histological response.Patients with resectable osteosarcoma aged ≤40 years were treated with the MAP regimen, comprising pre-operatively of two 5-week cycles of cisplatin 120 mg/m(2), doxorubicin 75 mg/m(2), methotrexate 12 g/m(2) × 2 (MAP) and post-operatively two further cycles of MAP and two cycles of just MA. Patients were randomised after surgery. Those with ≥10% viable tumour in the resected specimen received MAP or MAP with ifosfamide and etoposide. Those with <10% viable tumour were allocated to MAP or MAP followed by pegylated interferon. Longitudinal evaluation of quality of life was undertaken.Recruitment was completed to the largest osteosarcoma study to date in 75 months. Commencing March 2005, 2260 patients were registered from 326 centres across 17 countries. About 1334 of 2260 registered patients (59%) were randomised. Pre-operative chemotherapy was completed according to protocol in 94%. Grade 3-4 neutropenia affected 83% of cycles and 59% were complicated by infection. There were three (0.13%) deaths related to pre-operative chemotherapy. At definitive surgery, 50% of patients had at least 90% necrosis in the resected specimen.New models of collaboration are required to successfully conduct trials to improve outcomes of patients with rare cancers; EURAMOS-1 demonstrates achievability. Considerable regulatory, financial and operational challenges must be overcome to develop similar studies in the future. The trial is registered as NCT00134030 and ISRCTN 67613327.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CC66发布了新的文献求助10
刚刚
茯苓薏米茶完成签到,获得积分10
1秒前
256321完成签到,获得积分10
1秒前
2秒前
3秒前
3秒前
3秒前
sxxx完成签到,获得积分10
4秒前
5秒前
mcl完成签到,获得积分10
5秒前
善良雁完成签到 ,获得积分10
5秒前
科研通AI6.2的应助被一地狗粮采纳,获得10
6秒前
菜鸟完成签到,获得积分10
7秒前
柴胡完成签到,获得积分10
7秒前
现代的东蒽完成签到,获得积分10
7秒前
香蕉觅云的应助被1111采纳,获得10
8秒前
柏朴完成签到,获得积分10
8秒前
ID27149完成签到,获得积分10
8秒前
zhangsan发布了新的文献求助10
8秒前
干净的梦易完成签到,获得积分10
9秒前
9秒前
啦啦啦发布了新的文献求助10
9秒前
思源的应助被yang采纳,获得10
10秒前
10秒前
jkq完成签到,获得积分20
11秒前
11秒前
殷勤的烨霖完成签到 ,获得积分20
11秒前
李TB发布了新的文献求助10
11秒前
12秒前
Rony发布了新的文献求助10
12秒前
orixero的应助被开心弘文采纳,获得10
12秒前
13秒前
好好学习发布了新的文献求助10
13秒前
wanci的应助被shenmolianzzz采纳,获得10
13秒前
你的完成签到 ,获得积分10
14秒前
深情安青的应助被蝈蝈采纳,获得10
15秒前
bkagyin的应助被lili采纳,获得10
15秒前
朴素乐儿完成签到 ,获得积分10
16秒前
MingQue完成签到,获得积分0
16秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186012
求助须知:如何正确求助?哪些是违规求助? 9574616
关于积分的说明 21837084
捐赠科研通 7783730
什么是DOI,文献DOI怎么找? 3434729
关于科研通互助平台的介绍 2559055
邀请新用户注册赠送积分活动 2481504